Rock1 & 2 perform overlapping and unique roles in angiogenesis and angiosarcoma tumor progression

Current Molecular Medicine

Volumn 13, Issue 1, 2013, Pages 205-219

  Montalvo, J ^a   Spencer, C ^a,b   Hackathorn, A ^a   Masterjohn, K ^a   Perkins, A ^a,c   Doty, C ^a,d   Arumugam, A ^e   Ongusaha, P P ^b   Lakshmanaswamy, R ^e   Liao, J K ^b   Mitchell, D C ^e   Bryan, B A ^a,e  

^a WORCESTER STATE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

Angiogenesis; Cytoskeleton; Endothelial cell; Rho kinase; ROCK; Vascular endothelial growth factor

Indexed keywords

CASPASE 6; CASPASE 9; FIBROBLAST GROWTH FACTOR; MATRIGEL; PROTEIN SERINE THREONINE KINASE; ROCK 1 PROTEIN; ROCK 2 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; RHO KINASE; ROCK1 PROTEIN, MOUSE; ROCK2 PROTEIN, MOUSE; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANGIOGENESIS; ANGIOSARCOMA; ARTICLE; CARCINOGENESIS; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL SURVIVAL; CHORIOALLANTOIS; CONFOCAL LASER MICROSCOPY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; IMMUNOFLUORESCENCE; MICROARRAY ANALYSIS; NONHUMAN; OVERLAPPING GENE; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL MOTION; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEMANGIOSARCOMA; MELANOMA; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; RHO-ASSOCIATED KINASES; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883452065     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652413804486296     Document Type: Article

References (47)

1. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21: 247-69.
2. Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011; 32(3): 167-73.
3. Shimizu Y, Thumkeo D, Keel J, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 2005; 168(6): 941-53.
4. Thumkeo D, Keel J, Ishizaki T, et al. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 2003; 23(14): 5043-55.
5. Rikitake Y, Oyama N, Wang CY, et al. Decreasedperivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 2005; 112(19): 2959-65.
6. Noma K, Rikitake Y, Oyama N, et al. ROCK1 mediatesleukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008; 118(5): 1632-44.
7. Bryan BA, Dennstedt E, Mitchell DC, et al. RhoA/ROCKsignaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 2010; 24(9): 3186-95.
8. Leong SY, Faux CH, Turbic A, Dixon KJ, Turnley AM. TheRho kinase pathway regulates mouse adult neural precursor cell migration. Stem Cells 2010; 29(2): 332-43.
9. Daley WP, Gulfo KM, Sequeira SJ, Larsen M. Identificationof a mechanochemical checkpoint and negative feedback loop regulating branching morphogenesis. Dev Biol 2009; 336(2): 169-82.
10. Mong PY, Wang Q. Activation of Rho kinase isoforms in lungendothelial cells during inflammation. J Immunol 2009; 182(4): 2385-94.
11. Yoneda M, Hirokawa YS, Ohashi A, et al. RhoB enhancesmigration and MMP1 expression of prostate cancer DU145. Exp Mol Pathol 2010; 88(1): 90-5.
12. Orlando KA, Stone NL, Pittman RN. Rho kinase regulatesfragmentation and phagocytosis of apoptotic cells. Exp Cell Res 2006; 312(1): 5-15.
13. Inaba N, Ishizawa S, Kimura M, et al. Effect of inhibition ofthe ROCK isoform on RT2 malignant glioma cells. Anticancer Res 2010; 30(9): 3509-14.
14. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91(2): 143-50.
15. Hoang MV, Whelan MC, Senger DR. Rho activity criticallyand selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci USA 2004; 101(7): 1874-9.
16. Mavria G, Vercoulen Y, Yeo M, et al. ERK-MAPK signalingopposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 2006; 9(1): 33-44.
17. Yin L, Morishige K, Takahashi T, et al. Fasudil inhibitsvascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 2007; 6(5): 1517-25.
18. Hata Y, Miura M, Nakao S, Kawahara S, Kita T, Ishibashi T. Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor. Jpn J Ophthalmol 2008; 52(1): 16-23.
19. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, vanHinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol 2003; 23(2): 211-7.
20. Ghosh K, Thodeti CK, Dudley AC, Mammoto A, Klagsbrun M, Ingber DE. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc Natl Acad Sci USA 2008; 105(32): 11305-10.
21. Ribatti D, Nico B, Vacca A, Presta M. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc 2006; 1(1): 85-91.
22. Bryan BA, D'Amore PA. Pericyte isolation and use inendothelial/pericyte coculture models. Methods Enzymol 2008; 443: 315-31.
23. Spencer C, Montalvo J, McLaughlin SR, Bryan BA. Smallmolecule inhibition of cytoskeletal dynamics in melanoma tumors results in altered transcriptional expression patterns of key genes involved in tumor initiation and progression. Cancer Genomics Proteomics 2011; 8(2): 77-85.
24. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997; 94(3): 861-6.
25. Routhier A, Astuccio M, Lahey D, et al. Pharmacologicalinhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep 2010; 23(3): 861-7.
26. Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F. Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J Cell Biol 2000; 150(4): 797-806.
27. Hall A. Rho GTPases and the control of cell behaviour.Biochem Soc Trans 2005; 33(Pt 5): 891-5.
28. Street CA, Bryan BA. Rho kinase proteins--pleiotropicmodulators of cell survival and apoptosis. Anticancer Res 2011; 31(11): 3645-57.
29. Berenjeno IM, Bustelo XR. Identification of the Rock-dependent transcriptome in rodent fibroblasts. Clin Transl Oncol 2008; 10(11): 726-38.
30. Boerma M, Fu Q, Wang J, et al. Comparative geneexpression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008; 19(7): 709-18.
31. Harvey SA, Anderson SC, SundarRaj N. Downstream effectsof ROCK signaling in cultured human corneal stromal cells: microarray analysis of gene expression. Invest Ophthalmol Vis Sci 2004; 45(7): 2168-76.
32. Shi J, Wei L. Rho kinase in the regulation of cell death andsurvival. Arch Immunol Ther Exp (Warsz) 2007; 55(2): 61-75.
33. Yoneda A, Ushakov D, Multhaupt HA, Couchman JR. Fibronectin matrix assembly requires distinct contributions from Rho kinases I and -II. Mol Biol Cell. 2007 Jan;18(1):66-75.
34. Wang Y, Zheng XR, Riddick N, et al. ROCK isoformregulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res 2009; 104(4): 531-40.
35. Pinner S, Sahai E. PDK1 regulates cancer cell motility byantagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 2008; 10(2): 127-37.
36. Riento K, Guasch RM, Garg R, Jin B, Ridley AJ. RhoE bindsto ROCK I and inhibits downstream signaling. Mol Cell Biol 2003; 23(12): 4219-29.
37. Ingber DE. Tensegrity II. How structural networks influencecellular information processing networks. J Cell Sci 2003; 116(Pt 8): 1397-408.
38. Ingber DE. Tensegrity I. Cell structure and hierarchicalsystems biology. J Cell Sci 2003; 116(Pt 7): 1157-73.
39. Kamai T, Arai K, Sumi S, et al. The rho/rho-kinase pathwayis involved in the progression of testicular germ cell tumour. BJU Int 2002; 89(4): 449-53.
40. Kamai T, Tsujii T, Arai K, et al. Significant association ofRho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003; 9(7): 2632-41.
41. Kaneko K, Satoh K, Masamune A, Satoh A, Shimosegawa T.Expression of ROCK-1 in human pancreatic cancer: its down-regulation by morpholino oligo antisense can reduce the migration of pancreatic cancer cells in vitro. Pancreas 2002; 24(3): 251-7.
42. Zhou J, Zhao LQ, Xiong MM, et al. Gene expression profilesat different stages of human esophageal squamous cell carcinoma. World J Gastroenterol 2003; 9(1): 9-15.
43. Wong CC, Wong CM, Tung EK, Man K, Ng IO. Rho-kinase 2is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 2009; 49(5): 1583-94.
44. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000; 269(3): 652-9.
45. Rattan S, De Godoy MA, Patel CA. Rho kinase as a novelmolecular therapeutic target for hypertensive internal anal sphincter. Gastroenterology 2006; 131(1): 108-16.
46. Amine A, Rivera S, Opolon P, et al. Novel anti-metastaticaction of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. PLoS One 2009; 4(3): e5018.
47. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibitionof rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009; 69(22): 8742-51.